Home

Welcome back to our monthly series: What’s Trending in AI-Assisted Health. Here are five fresh developments to know for October 2025 — spanning post-viral diagnostics, drug discovery, always-on wearables, clinical pilots, and governance.

AI Finds Blood Biomarkers Linked to Long COVID

NIH- and university-led teams applied large models to immune and metabolomic data and reported signatures that distinguish post-acute COVID conditions from matched controls. Early, but promising for future diagnostics and trial stratification. (NIH, Nature Medicine)

AI-Driven Drug Repurposing Advances for Rare Diseases

Model-based pipelines from leading labs prioritized existing compounds for rare neuromuscular and metabolic disorders; several candidates progressed to preclinical testing this fall — a faster road from in silico to in vivo. (DeepMind, Lancet Digital Health)

Wearables 2.0: From Steps to Continuous Biomarkers

Smart rings and skin patches now estimate glucose, cortisol, and hydration trends via optical sensing and on-device AI, nudging personal health from episodic checks to preventive, 24/7 analytics. (IEEE Spectrum, MedTech Dive)

Clinician Co-Pilot: Generative Models Inside EMRs

Hospitals piloting EMR-integrated models (e.g., MedLM with Epic) report time-savings on chart summaries, after-visit plans, and guideline prompts — with clinicians firmly in the loop. (Google Health, Epic Newsroom)

WHO Publishes Guidance on Generative AI in Health

WHO issued principles for safe, equitable deployment of genAI in care and public health: robust evaluation, bias measurement, human oversight, and post-market monitoring. (WHO, Reuters Health)

Bottom line: AI in health is moving from hype to hard problems — persistent conditions, neglected diseases, real-world workflows, and governance. The throughline: evaluation and oversight.

⬐ Understand Your Lab Results in Seconds ⬎

Try ai-labtest.com →